Bajaj Healthcare gets nod to conduct Clinical Trial, Bioequivalence Study of Suvorexant Tablets

01 Jan 2026 Evaluate

Bajaj Healthcare has received approval from Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct Clinical Trial and Bioequivalence Study of Suvorexant Tablets.

Earlier, the company had received a positive recommendation from the Subject Expert Committee (Neurology & Psychiatry) of the CDSCO to initiate Phase III clinical trials for Suvorexant Tablets, available in strengths of 5mg, 10mg, 15mg, and 20mg.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

425.00 0.10 (0.02%)
02-Jan-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.70
Dr. Reddys Lab 1240.70
Cipla 1506.80
Zydus Lifesciences 913.85
Lupin 2106.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×